4.2 Article

Red blood cells stored 35 days or more are associated with adverse outcomes in high-risk patients

期刊

TRANSFUSION
卷 56, 期 7, 页码 1690-1698

出版社

WILEY
DOI: 10.1111/trf.13559

关键词

-

资金

  1. Haemonetics Corp. (Braintree, MA)

向作者/读者索取更多资源

BACKGROUNDClinical trials have shown that longer red blood cell (RBC) storage duration does not worsen outcomes; however, these studies included few RBCs near the end of the 42-day storage limit. We tested the hypothesis that these oldest RBCs are associated with adverse outcomes. STUDY DESIGN AND METHODSIn a retrospective study, 28,247 transfused patients given 129,483 RBC units were assessed. Morbidity, mortality, and length of stay (LOS) were compared in patients transfused exclusively with RBCs stored not more than 21 days versus patients transfused exclusively with RBCs stored 28 days or more and patients transfused exclusively with RBCs stored 35 days or more. RESULTSAfter risk adjustment, 35-day RBCs were associated with increased morbidity (adjusted odds ratio [adjOR], 1.19; 95% confidence interval [CI], 1.07-1.32; p = 0.002), but 28-day RBCs were not (adjOR, 1.06; 95% CI, 0.97-1.15; p = 0.2). Neither 35-day nor 28-day RBCs were associated with increased mortality. In critically ill patients, 35-day RBCs were associated with increased morbidity (adjOR, 1.25; 95% CI, 1.08-1.44; p = 0.002) and mortality (adjOR, 1.38; 95% CI, 1.08-1.74; p = 0.009), but 28-day RBCs were associated with neither. In older patients, 35-day RBCs were associated with increased morbidity (adjOR, 1.22; 95% CI, 1.04-1.42; p = 0.01), but not mortality (adjOR, 1.28; 95% CI, 0.96-1.71; p = 0.1), and 28-day RBCs were associated with neither. LOS was increased for both 28- and 35-day RBCs for all patients and the critically ill and older subgroups. CONCLUSIONSRBCs transfused in the last 7 days of their 42-day storage limit may be associated with adverse clinical outcomes in high-risk patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据